Horizon Therapeutics plc
1 products found
Horizon Therapeutics plc products
Pipeline
Horizon - Diffuse Cutaneous Systemic Sclerosis
A molecule that blocks lysophosphatidic acid receptor 1 (LPAR1). We are conducting a Phase 2b pivotal trial in diffuse cutaneous systemic sclerosis and a Phase 2b pivotal trial in idiopathic pulmonary fibrosis.
